Key Highlights

  • Medline closed down 12.79% at $36.67 on August 5, reversing earlier gains despite beating second-quarter estimates.
  • Second-quarter net sales grew 12% year-over-year to $7.7 billion, with adjusted EBITDA rising 13% to $1.1 billion, both beating expectations.
  • The company cut its full-year adjusted EBITDA guidance range to $3.3 billion to $3.4 billion, down from $3.5 billion to $3.6 billion, reflecting Middle East conflict inflationary pressure, Tracy Fire costs, quality remediation, and retail softness.
  • A mid-June fire at the company's Tracy, California distribution center resulted in a $336 million cost impact, partially offset by $50 million to $100 million in expected insurance recovery.
  • Full-year organic sales guidance was raised for the second time this year to 9% to 10%, up from a prior 8.5% to 9.5% range.

What Happened

Medline (NASDAQ:MDLN) is the largest provider of medical-surgical products and supply chain solutions in the United States, serving hospitals, surgical centers, physician offices, post-acute care facilities, and nursing homes both domestically and internationally. Founded in 1966 and headquartered in Northfield, Illinois, the company operates through its Medline Brand and Supply Chain Solutions segments, offering a portfolio of approximately 335,000 med-surg products.

Shares tumbled on August 5 despite the company beating second-quarter estimates on both revenue and earnings, as investors focused on a cut to full-year adjusted EBITDA guidance driven by a combination of one-time and structural cost pressures. Second-quarter net sales grew 12% year-over-year to $7.7 billion, with adjusted EBITDA up 13% to $1.1 billion, both topping expectations, and adjusted EBITDA margin at 14.1% for the quarter.

Guidance Cut Drives the Decline

The primary driver of today's decline was management's decision to lower full-year adjusted EBITDA guidance to a range of $3.3 billion to $3.4 billion, down from a prior range of $3.5 billion to $3.6 billion, reflecting reduced Middle East conflict inflationary pressure, Tracy Fire costs, operational investments, quality remediation, and retail softness. A mid-June fire at the company's Tracy, California distribution center resulted in a $336 million cost impact, excluded from adjusted EBITDA, with an additional $50 million to $100 million expected in H2 2026, though a new distribution center is expected to open in the fourth quarter of 2026 with a Stockton facility expanding California footprint to nearly 5 million square feet by mid-2027.

Full-year tariff impact estimate was reduced to approximately $350 million, down from a prior $490 million estimate, due to Section 122 tariffs being repealed and $507 million in tariff refunds expected, with $89 million already repaid to customers. New customer signings reached over $650 million through the first half of 2026, 65% of the full-year goal, including a new prime vendor agreement with Allina Health, while the company reduced net leverage to 2.9x, achieving its long-term leverage goal, with $920 million free cash flow through the first half.

Organic Growth Raised Despite Margin Pressure

Notably, full-year organic sales guidance was raised for the second time this year to 9% to 10%, up from 8.5% to 9.5% previously, signaling continued underlying demand strength even as near-term margin pressures weigh on the profitability outlook. The combination of raised top-line guidance alongside cut EBITDA guidance appears to reflect a company absorbing multiple simultaneous cost headwinds while still growing its customer base and market share.

Conclusion

Medline's second-quarter beat was overshadowed by the scale of its full-year EBITDA guidance cut, with the Tracy distribution center fire, tariff dynamics, and Middle East-related cost pressures combining to weigh on near-term profitability even as organic growth guidance was raised. Investors will likely watch closely for signs that the Stockton facility expansion and insurance recovery can help restore margin trajectory in coming quarters.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.